Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Diffuse Large B-Cell Lymphoma

  • Ken H. Young
  • Michael B. Møller
Living reference work entry

Latest version View entry history

DOI: https://doi.org/10.1007/978-3-642-27841-9_1618-4

Synonyms

Definition

Diffuse large B-cell lymphoma is an entity of non-Hodgkin lymphoma composed of malignant large lymphoid cells with blastic morphologic features, expression of B-cell markers, and a diffuse growth pattern. The postulated cells of origin are germinal or post germinal center B-cells. This lymphoma entity is morphologically, clinically, and molecularly heterogeneous.

Characteristics

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma comprising 30–40 % of non-Hodgkin lymphomas in adult and approximately 20 % in childhood and adolescence. Diffuse large B-cell lymphoma can be seen in all age groups, but the incidence increases with age. The median age at diagnosis is approximately 65 years. There is a slight male preponderance (1.2:1). In most patients, the...

Keywords

Chronic Lymphocytic Leukemia Follicular Lymphoma International Prognostic Index Anaplastic Large Cell Lymphoma Primary Effusion Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Armitage JO, Mauch PM, Harris NL et al (2004) Diffuse large B-cell lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL (eds) Non-Hodgkin’s lymphomas. Lippincott Williams & Wilkins, Philadelphia, pp 427–453Google Scholar
  2. Gatter KC, Warnke RJ (2001) Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 171–174Google Scholar
  3. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715–2724, 4/2013CrossRefPubMedPubMedCentralGoogle Scholar
  4. Küppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251–262CrossRefPubMedGoogle Scholar
  5. Ok CY, Papathomas TG, Medeiros LJ, Young KH (2013) EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 122(3):328–340CrossRefPubMedPubMedCentralGoogle Scholar
  6. Staudt LM, Dave S (2005) The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 87:163–208CrossRefPubMedPubMedCentralGoogle Scholar
  7. Stein H, Warnke RA, Chan WC et al (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoetic and lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 233–261Google Scholar
  8. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O’Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103–2113CrossRefPubMedPubMedCentralGoogle Scholar
  9. Xia Y, Medeiros LJ, Young KH (2016) Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 1865(1):58–71PubMedGoogle Scholar
  10. Young KH, Medeiros LJ, Chan WC (2014) Diffuse large B-cell lymphoma. In: Orazi A, Weiss LM, Foucar K, Knowles DM (eds) Neoplastic hematopathology. Lippincott Willaims & Wilkins, Philadelphia, pp 502–565Google Scholar

See Also

  1. (2012) B symptoms. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 331. doi:10.1007/978-3-642-16483-5_511Google Scholar
  2. (2012) BCL-6. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 363–364. doi:10.1007/978-3-642-16483-5_566Google Scholar
  3. (2012) Bulky. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 574. doi:10.1007/978-3-642-16483-5_752Google Scholar
  4. (2012) CD20. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 693. doi:10.1007/978-3-642-16483-5_922Google Scholar
  5. (2012) CD30. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 697. doi:10.1007/978-3-642-16483-5_926Google Scholar
  6. (2012) CD95. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 703. doi:10.1007/978-3-642-16483-5_939Google Scholar
  7. (2012) Class switching. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 879. doi:10.1007/978-3-642-16483-5_1203Google Scholar
  8. (2012) Doxorubicin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1159. doi:10.1007/978-3-642-16483-5_1722Google Scholar
  9. (2012) Germinal center. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1541. doi:10.1007/978-3-642-16483-5_2401Google Scholar
  10. (2012) Immunoglobulin genes. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1819. doi:10.1007/978-3-642-16483-5_2992Google Scholar
  11. (2012) Ki-67. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1943. doi:10.1007/978-3-642-16483-5_3213Google Scholar
  12. (2012) Non-Hodgkin lymphoma. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2537. doi:10.1007/978-3-642-16483-5_4110Google Scholar
  13. (2012) Prednisone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2972. doi:10.1007/978-3-642-16483-5_4720Google Scholar
  14. (2012) Somatic hypermutation. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 3466–3467. doi:10.1007/978-3-642-16483-5_5410Google Scholar
  15. (2012) Vincristine. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3908. doi:10.1007/978-3-642-16483-5_6188Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2016

Authors and Affiliations

  1. 1.Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of PathologyOdense University HospitalOdenseDenmark